title: [Focal immunophysiotherapy in combined treatment of men with manifestations of papilloma virus infection].
abstract: We compared efficacy of combined treatment of males with anogenital warts given intramuscular cycloferon or cycloferon electrophoresis. Patients with manifest HPV infection (n=107) were divided into two groups. Group 1 (n=72) received intramuscular cycloferon (2 ml 12.5% solution each other day for 10 days), group 2 (n=35) received cycloferon electrophoresis on genital region (2 ml 12.5% solution daily in 1-2 days, 5 injections). Measurements were made of local cytokines in urethral secretion, IFN-alpha, IFN-gamma, lactoferrin, sexual hormones (estradiol and testosterone) in blood serum before and after treatment. Focal immunophysiotherapy with cycloferon in combined treatment of males with anogenital warts vs intramuscular cycloferon treatment reduces recurrence rate 2 times, has no negative effect on serum level of sexual hormones, a course dose and duration of immunotherapy decreased 2-fold, is well tolerated, is not painful. Cycloferon electrophoresis has a more potent effect on improvement of local immunity. Thus, local immunophysiotherapy with cycloferon can be a method of choice in the treatment of manifest HPV infection in males.
authors.forename: L D
authors.initials: LD
authors.lastname: Kuntsevich
authors.forename: N N
authors.initials: NN
authors.lastname: Komov
authors.forename: E V
authors.initials: EV
authors.lastname: Shibaeva
authors.forename: V D
authors.initials: VD
authors.lastname: Komarova
authors.forename: T V
authors.initials: TV
authors.lastname: Kopytova
authors.forename: E I
authors.initials: EI
authors.lastname: Pyshkina
authors.forename: N A
authors.initials: NA
authors.lastname: Shchelchkova
mesh_terms: D000166:Acridines / Q000008:administration & dosage / Q000627:therapeutic use; D000287:Administration, Topical; D000328:Adult; D003131:Combined Modality Therapy; D003218:Condylomata Acuminata / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D053672:Electrochemotherapy / Q000379:methods*; D004564:Electrocoagulation / Q000379:methods; D004958:Estradiol / Q000097:blood; D005832:Genital Diseases, Male / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007273:Injections, Intramuscular; D007369:Interferon Inducers / Q000008:administration & dosage / Q000627:therapeutic use; D016898:Interferon-alpha / Q000097:blood / Q000276:immunology; D007371:Interferon-gamma / Q000097:blood / Q000276:immunology; D008297:Male; D013739:Testosterone / Q000097:blood; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000166:Acridines; D007369:Interferon Inducers; D016898:Interferon-alpha; D013739:Testosterone; D004958:Estradiol; D007371:Interferon-gamma; C026430:10-carboxymethyl-9-acridanone